中国医药
中國醫藥
중국의약
CHINA MEDICINE
2015年
6期
879-881
,共3页
精神分裂症%阿立哌唑%奥氮平%不良反应
精神分裂癥%阿立哌唑%奧氮平%不良反應
정신분렬증%아립고서%오담평%불량반응
Schizophrenia%Aripiprazole%Olanzapine%Adverse reaction
目的 探讨阿立哌唑治疗精神分裂症的临床疗效和不良反应.方法 纳入2013年7月至2014年6月就诊于解放军第四二二医院的精神分裂症患者100例,完全随机分为阿立哌唑组和奥氮平组,各50例.阿立哌唑组口服阿立哌唑片,最大剂量30 mg/d;奥氮平组口服奥氮平片,最大剂量20 mg,/d,疗程均为8周.于治疗前,治疗后2、4、6、8周评估阳性与阴性症状量表(PANSS)评分,判定临床疗效;采用治疗出现症状量表(TESS)评估不良反应发生情况.结果 治疗前2组PANSS评分总分差异无统计学意义(P＞0.05),治疗后2、4、6和8周后阿立哌唑组和奥氮平组PANSS评分总分均较治疗前均明显下降[阿立哌唑组:(75±13)、(60±13)、(50±10)、(46±12)分比(90±15)分;奥氮平组:(78±l4)、(63±12)、(52±12)、(49±12)分比(90±15)分;均P＜0.05].阿立哌唑组总有效率高于奥氮平组[94.0％(47/50)比90.0％(45/50),P＜0.05).阿立哌唑组和奥氮平组均未发生严重不良反应,阿立哌唑组不良反应发生率低于奥氮平组[46.0％(23/50)比70.0％(35/50),P＜0.05].结论 阿立哌唑治疗精神分裂症疗效优于奥氮平,安全性较好.
目的 探討阿立哌唑治療精神分裂癥的臨床療效和不良反應.方法 納入2013年7月至2014年6月就診于解放軍第四二二醫院的精神分裂癥患者100例,完全隨機分為阿立哌唑組和奧氮平組,各50例.阿立哌唑組口服阿立哌唑片,最大劑量30 mg/d;奧氮平組口服奧氮平片,最大劑量20 mg,/d,療程均為8週.于治療前,治療後2、4、6、8週評估暘性與陰性癥狀量錶(PANSS)評分,判定臨床療效;採用治療齣現癥狀量錶(TESS)評估不良反應髮生情況.結果 治療前2組PANSS評分總分差異無統計學意義(P＞0.05),治療後2、4、6和8週後阿立哌唑組和奧氮平組PANSS評分總分均較治療前均明顯下降[阿立哌唑組:(75±13)、(60±13)、(50±10)、(46±12)分比(90±15)分;奧氮平組:(78±l4)、(63±12)、(52±12)、(49±12)分比(90±15)分;均P＜0.05].阿立哌唑組總有效率高于奧氮平組[94.0％(47/50)比90.0％(45/50),P＜0.05).阿立哌唑組和奧氮平組均未髮生嚴重不良反應,阿立哌唑組不良反應髮生率低于奧氮平組[46.0％(23/50)比70.0％(35/50),P＜0.05].結論 阿立哌唑治療精神分裂癥療效優于奧氮平,安全性較好.
목적 탐토아립고서치료정신분렬증적림상료효화불량반응.방법 납입2013년7월지2014년6월취진우해방군제사이이의원적정신분렬증환자100례,완전수궤분위아립고서조화오담평조,각50례.아립고서조구복아립고서편,최대제량30 mg/d;오담평조구복오담평편,최대제량20 mg,/d,료정균위8주.우치료전,치료후2、4、6、8주평고양성여음성증상량표(PANSS)평분,판정림상료효;채용치료출현증상량표(TESS)평고불량반응발생정황.결과 치료전2조PANSS평분총분차이무통계학의의(P＞0.05),치료후2、4、6화8주후아립고서조화오담평조PANSS평분총분균교치료전균명현하강[아립고서조:(75±13)、(60±13)、(50±10)、(46±12)분비(90±15)분;오담평조:(78±l4)、(63±12)、(52±12)、(49±12)분비(90±15)분;균P＜0.05].아립고서조총유효솔고우오담평조[94.0％(47/50)비90.0％(45/50),P＜0.05).아립고서조화오담평조균미발생엄중불량반응,아립고서조불량반응발생솔저우오담평조[46.0％(23/50)비70.0％(35/50),P＜0.05].결론 아립고서치료정신분렬증료효우우오담평,안전성교호.
Objective To explore the clinical effect of aripiprazole in treatment of schizophrenia.Methods Totally 100 patients with schizophrenia from July 2013 to June 2014 were enrolled and randomly divided into aripiprazole group (50 cases) taking aripiprazole orally (the maximum dosage 30 mg/d) for 8 weeks,and olanzapine group (50 cases) taking olanzapine orally (the maximum dosage 20 mg/d) for 8 weeks.The postive and negative syndrome scale (PANSS) score was assessed before and 2,4,6,8 weeks after treatment;the effective rate was calculated and compared between the two groups.The treatment.emergent symptom scale (TESS) was assessed to evaluate the adverse reactions.Results No significant differences of PANSS score before treatment were shown between the two groups.The PANSS scores 2,4,6 and 8 weeks after treatment were significantly reduced compared with those before treatment in both aripiprazole groups [total PANSS score:(75 ± 13) scores,(60 ± 13) scores,(50 ± 10) scores,(46 ± 12) scores vs (90 ± 15) scores] and olanzapine group [(78 ± 14) scores,(63 ±12) scores,(52 ± 12) scores,(49 ± 12) scores vs (90 ± 15) scores] (all P ＜0.05).The effective rate in aripiprazole group was statistically higher than that in olanzapine group [94.0(47/50) vs 90.0％ (45/50),P ＜ 0.05].No serious adverse reactions occurred in both groups;the incidence of adverse reaction in aripiprazole group was significantly lower than that in olanzapine group [46.0％ (23/50) vs 70.0％ (35/50),P ＜0.05].Conclusion The clinical effect of aripiprazole is better than olanzapine regarding treatment of schizophrenia.
